Hyperlipidemia drug statin combination therapy lowers the risk of blood cancer death by 61%
Apr 24, 2025
|
The researchers conducted a study on 1,467 patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, a type of blood cancer.
About a third of them were taking statins used to treat hyperlipidemia.
The researchers divided it into three groups: ▲dose of the new anticancer drug ibrutinib alone ▲statin and combination therapy ▲drug therapy without ibrutinib.
After about 5 years of follow-up, patients who received both statins and ibrutinib had a 61% lower risk of dying from cancer compared with those who did not.
In addition, the researchers found that patients taking statins had a 38% lower risk of death from all causes and a 26% lower risk of disease progression.
However, the study was only observed and could not prove a direct reason for statins to reduce risk, the researchers said.
Dr. Ahmad Abuelwa of the University of Sharjah evaluated "The results of this study showed a strong link between statin use and improved survival in patients with blood cancer.". "However, based on this study alone, we cannot recommend starting statins for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.""Future clinical trials are needed to determine whether statins have a direct benefit to cancer survival rates" he added.
On the other hand, statins are widely used drugs for dyslipidemia and hyperlipidemia. It is known to significantly lower cardiovascular abnormalities and mortality caused by these diseases.
Previous published studies have suggested that statins can significantly reduce the risk of colorectal cancer, prostate cancer, and ovarian cancer.
This article was translated by Naver AI translator.
